MedTrace Logo

Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

NCT02162979 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-03-30

Study results available
· View outcomes & findings →

Summary

This study is to determine if Viagra is effective in reducing dyskinesias in patients with Parkinson's Disease.

Conditions

Interventions

DRUG

sildenafil

sildenafil 50mg BID for 2 weeks

DRUG

Placebo

Sponsors & Collaborators

  • Loma Linda University

    lead OTHER

Principal Investigators

  • David M. Swope, MD · Loma Linda University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28
Primary Completion
2009-01-31
Completion
2009-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02162979 on ClinicalTrials.gov